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Prognostic significance of 18FDG PET/CT in
colorectal cancer patients with liver
metastases: a meta-analysis
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Abstract
Background: The role of 18-fluorodeoxyglucose positron emission tomography CT (18FDG PET/CT), as a prognostic
factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a
meta-analysis of the literature to address this issue.
Methods: A systematic literature search was performed to identify the studies that associated 18FDG PET/CT to
clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were
also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according
to heterogeneity between trails.
Results: By analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the
therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and
the HR was 0.45 (95 % confidence interval [CI], 0.26–0.78) and 0.36 (95 % CI, 0.18–0.71), respectively. Furthermore,
pre-treatment 18FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with
poorer OS HR, 1.24; (95 % CI, 1.06–1.45). However, we did not find a statistically significant effect of post-treatment
SUV for predicting OS HR, 1.68; (95 % CI, 0.63–4.52).
Conclusions: The present meta-analysis confirms that 18FDG PET/CT is a useful tool to help predict survival
outcomes in patients with liver metastases.
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Background
The liver is the most common site for hematogenous
spreading of metastatic neoplasms. Metastases can result
from a wide variety of malignancies, with the most
widely known being from colorectal origins. Previous
study indicated that liver metastases were detected in
40–50 % of nearly one million patients who were diag-
nosed with colorectal cancer worldwide each year [1]. In
the past, only 10 % of such patients with liver metastases
were eligible to surgery. New chemotherapy regimens
and improvement in surgical techniques have now
allowed surgically treating patients with liver metastases
in more advanced stages of illness. Radioembolization
using yttrium-90 (90Y) resin, also known as selective in-
ternal radiation therapy (SIRT), is a palliative treatment,
which reduces the liver tumor mass and might eventu-
ally permit surgical resection. However, treatment out-
comes of liver metastases remain heterogeneous.
Therefore, finding reliable prognostic indicators or bio-
markers, especially with those non-invasive imaging
methods, would be very helpful in the management of
patients with liver metastases, which has aroused great
research and clinical interests.
Over the recent decades, 18-fluorodeoxyglucose posi-
tron emission tomography (18FDG PET/CT) has played
an increasing role in clinical management of liver metas-
tases. Unlike traditional anatomical imaging modalities,
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PET/CT can provide not only morphological but also
functional information in a single session [2]. In particular,
18FDG as a glucose analogue has become the most popu-
lar PET tracer to visualize abnormal glucose metabolism
in oncology. Because enhanced glucose metabolism is re-
lated to the aggressiveness of cancer cells, 18FDG PET/CT
yielded superior results in monitoring therapy response
and predicting survival in patients with a range of malig-
nant tumors [3–7]. The changes in tumor size and/or
tumor number, which reflect the number of neoplastic
cells, can be used as a radiological or anatomic indicator
of the tumor response [8]. Nowadays, 18F-FDG PET/CT
has been used frequently for the assessment of therapeutic
responses. It is particularly preferred over anatomical im-
aging in patients receiving noncytotoxic therapy as it
returns to normal much more quickly [9]. Although the
tumoral 18F-FDG uptake tends to vary for a number of
reasons, there is a direct correlation between 18F-FDG up-
take and viable tumor cells. In addition, previous research
[10] found a significant agreement between anatomic and
metabolic criteria. Recent studies have correlated high
18FDG uptake in tumors with poorer patient survival
in lung, breast, head and neck, and esophageal can-
cers [11–13]. Furthermore, pretreatment tumoral 18FDG
uptake has been shown to represent an independent prog-
nostic factor in patients with liver metastases undergoing
whatever primary treatment modalities [14, 15]. At
present, a frequently used quantitative method in PET is
the standardized uptake value (SUV). Compared with
various other quantitative approaches, clinical appeal of
SUV lies in its simplicity and high reproducibility, thanks
to implemented modern computer software. It plays an
important role in the evaluation of patient responses to
therapies. Practitioners rely heavily on changes in SUVs
over time, in the absence of clear improvement or pro-
gression of disease by detection of previous lesions or new
lesions, respectively, to decide whether to continue or
switch therapies. Thus, not surprisingly, an overwhelming
volume of SUV data has accrued in PET-related oncologic
literature during recent decade. However, the results
about the prognostic value of SUV from 18FDG-PET/CT
in colorectal cancer patients with liver metastases remain
uncertain due to small sample size, various inclusion cri-
teria, and different data analysis strategies. Therefore,
through a current literature review, for the first time to
our knowledge, we have performed a meta-analysis to as-
sess the prognostic value of SUV from 18FDG-PET/CT for
the survival of patients with liver metastases.
Methods
Search strategy
We searched PUBMED, EMBASE, and MEDLINE for
articles published between January 2000 and March
2015 to identify the studies evaluating the prognostic
value of 18FDG PET/CT in long-term survival prediction
for patients with liver metastases. We used following
search terms: liver metastases, 18FDG PET/CT, progno-
sis, and survival. If overlapping patient cohorts were
used between several studies, we only retained the latest
or the largest study to avoid duplication of information.
When key information for meta-analysis was missing,
we contacted the researchers of selected studies for sup-
plying additional data. Only articles published in English
were included. As this analysis is merely a retrospective
literature review, neither Institutional Review Board ap-
proval nor informed consent was required by national
and regional laws.
Inclusion criteria
The eligibility of abstracts and full texts were assessed
by three reviewers independently. Disagreements were
resolved by discussion. Studies on which agreement
could not be accessed were all included for full text
screening. According to a previous report [16], the rele-
vant studies were manually selected carefully based on
the following criteria: 1) include more than 10 colorectal
cancer patients with liver metastases who underwent
treatments; 2) use once 18FDG PET/CT scan (pretreat-
ment or post-treatment) or twice 18FDG PET/CT scans
(pretreatment and post-treatment) to predict the survival
of patients, where PET/CT was evaluated alone or in
comparison to other tests; 3) report prognostic out-
comes such as overall survival (OS), progression-free
survival (PFS), disease-free survival (DFS) and relapse-
free survival (RFS), and compare the outcomes between
positive and negative results of 18FDG PET/CT; and 4)
contain extractable survival data of hazard ratio. How-
ever, reviews and other editorial materials were excluded
and the studies only focusing on the performance of
18FDG PET/CT in diagnosis, staging, and monitoring re-
currence or metastasis were also excluded. In addition,
reports concerning patients with suspected or diagnosed
recurrent disease were not adopted.
Qualitative assessment
Three investigators reviewed all the publications to as-
sess their methodological quality, determine their eligi-
bility for inclusion in the quantitative meta-analysis and
extract the most important information determining the
clinical and 18FDG PET/CT characteristics. As shown in
Table 1, a methodological quality scale has been adapted
from a previous study [17] for the purpose of this study
using the variables available from the publications. The
clinical report and 18FDG PET/CT report were scored
on 30 and 18 points respectively. A value between 0 and
2 was attributed to each item. When items were not ap-
plicable to a particular study, they were ruled out. The
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scores were expressed in percentage of the maximal the-
oretical value that could be obtained.
Data extraction and analyses
From those selected articles, two independent reviewers
extracted the data that include the first author, publica-
tion year, study design, sample size, PET/CT timing, type
of treatment received and end points for evaluating the
prognostic performance. Specifically, PFS or RFS were
merged as one outcome newly defined as event-free sur-
vival (EFS), which was measured from the date of ther-
apy initiation to the date of recurrence or progression.
We took overall survival (OS) as another outcome index.
Patients underwent once PET/CT scan (pre- or post-
treatment) were divided into high SUV and low SUV
groups according to SUV cutoff values or visual observa-
tion. In patients underwent twice PET/CT scans (pre-
treatment and post-treatment), the difference between
baseline and follow-up SUV values (ΔSUV) was used to
differentiate responding from nonresponding based on
the definition in each individual study. Survival data
from all studies were analyzed by means of the Kaplan-
Meier curves, unless hazard ratios (HRs) were reported
and compared to calculate HR and 95 % confidence in-
tervals (CI) as previously described by Parmar et al. [18]
and Tierney et al. [19]. These effects were combined to
compare the low SUV or metabolic responding and high
SUV or metabolic nonresponding arms for the overall
effect. If the numerator and denominator appeared op-
posite in an article, we chose to use ln(HR) and the gen-
eric inverse variance method in software Review
Manager 5.3.0 to get a result. HR < 1 indicated the sur-
vival benefit from a metabolic responding low SUV,
whereas HR > 1 denoted an increased risk of metabolic
nonresponding progression and death. It is considered
statistically significant when a P-value is less than 0.05.
Statistical heterogeneity was measured using the chi-
square Q test, while P < 0.10 was considered to represent
Table 1 A methodological quality scale of publications
Assessment parameter Scale
Clincal reports Prognostic factors Age 0 2
Gender 0 2
Performance status 0 2
Tumor characteristics Location of primary tumor 0 2
Number of metastatic sites 0 2
Size of hepatic metastasis 0 2
Differentiation grade 0 2
Description of the results of survival analysis Number of patients 0 2
Number of deaths 0 2
Follow-up duration 0 2
Number of patients lost to follow-up 0 2
Univariate and multivariate analyses 0 2
Description of statistical tests 0 2
Survival definition 0 2
SUV cutoff definition or response definition 0 2
Subscores
PET/CT reports Patients’ Characteristics Weight 0 2
Glycaemia 0 2
18FDG PET acquisition protocol characteristics Injected dose of 18FDG 0 2
Delay between injection 0 2
Data acquisition 0 2
Fasting duration 0 2
Technical Parameters SUV formula 0 2
Type of PET/CT engine 0 2
Type of SUV attenuation and reconstruction parameters 0 2
Subscores
Total scores
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significant statistical heterogeneity, and expressed by the
I2 statistic, as described by Higgins et al. [20]. Funnel
plot was performed for testing publication bias. Survival
rates on the graphical survival curves were read by soft-
ware Engauge Digitizer version 4.1. (Trolltech, Oslo,
Norway). HRs and their variations were calculated by
Review Manager 5.3.0 (The Nordic Cochrane Centre,
Copenhagen, Denmark).
Results
Study inclusion and characteristics analyses
An internet-based electronic search resulted in 196 po-
tentially eligible articles from all databases. Among
them, 147 articles were excluded based on their ab-
stracts, including 3 non-English articles, 4 case reports,
7 reviews, and 133 articles that were irrelevant to prog-
nostic performance of 18FDG PET/CT in patients with
liver metastases. The remaining 49 full-text articles were
further analyzed for eligibility. Of these studies 33 were
excluded because the log HR and its variance could not
be calculated and one article was only excluded for in-
accessible full text. Finally, a total of 15 studies were de-
termined to be qualified for the actual meta-analysis.
Figure 1 illustrates the inclusion process and reasons for
exclusion. Finally, a total of 867 patients from these 15
studies were analyzed, and the characteristics of selected
studies are described in Table 2. The main SUV and
ΔSUV characteristics reported in the publication are pre-
sented in Tables 3 and 4.
Qualitative assessment
Overall, the publications’ quality score ranged from 50
to 83.33 %, with a median score of 68.33 % (Table 2). If
necessary, we attempted to contact the authors to gain
missing details of the methodological quality.
Meta-analyses
Predictive value of ΔSUV for EFS
A total of 7 studies focused on predictive value of ΔSUV
for EFS, 5 studies showed that there were significant dif-
ferences between responding and nonresponding groups
for EFS prognosis, 1 study did not indicate this outcome.
Figure 2 shows the results of meta-analysis of the 7 stud-
ies containing 247 patients comparing EFS in the
responding group with that in the non-responding group
(P < 0.0001). With a summarized HR less than 1, it
suggests a survival advantage for the responding
group. We find heterogeneity between the studies (I2 =
0 %, P = 0.84). In pooled analysis, EFS was significantly
better in responding group, 0.45 (95 % CI, 0.26–0.78) by
random model.
Predictive value of ΔSUV for OS
Seven studies covering 334 patients were analyzed in this
comparison. With I2 = 82 %, the heterogeneity could not
be ignored between the studies. Thus, we chose random
model to calculate the summarized HR, 0.36 (95 % CI,
0.18-0.71), suggesting that the OS was significantly better
with responding group (P = 0.004) as revealed in Fig. 3.
Predictive value of pretreatment SUV for OS
As displayed in Fig. 4, six studies involving 509 patients
were evaluated in this comparison. The OS disadvantage
for high SUV PET/CT images over low SUV ones was
statistically significant (P = 0.008), the test for heterogen-
eity was no statistically significant (I2 = 46 %, P = 0.10).
By fixed-effects model with a summarized HR, 1.24
Fig. 1 Flow chart of the studies selection process
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(95%CI, 1.06–1.45), it suggests that high SUV PET/CT
results were associated with poor OS.
Predictive value of post-treatment SUV for OS
Three other studies including 55 patients were assessed
to estimate the prognostic value for predicting OS by
post-treatment PET/CT. The results are demonstrated
in Fig. 5, indicating that there was no statistically
significance between high SUV PET/CT group and low
SUV PET/CT group for OS, HR, 1.68; (95%CI, 0.63–
4.52), P = 0.30. There was significant heterogeneity be-
tween researches (I2 = 67 %; P = 0.08).
Discussion
Recently, the degree of tumor uptake of 18FDG on PET
as assessed by the SUV was shown to be an independent
Table 2 Principal characteristics of the 15 studies included in the meta-analysis
Study Publication year Number of
patients
Study design PET/CT timing Type of treatment End pointsa Methodology
score (%)
de Geus-Oei L F et al. 2006 152 Retrospective Pretreatment Resection or
Chemotherapy
OS 83.33 %
Small RM et al. [21] 2009 54 retrospective Pretreatment and
posttreatment
Chemotherapy OS EFS(PFS) 50.00 %
Hendlisz A et al. 2011 41 Prospective Pretreatment and
posttreatment
Chemotherapy OS EFS(PFS) 70.83 %
Muralidharan V et al. 2012 30 retrospective Pretreatment Resection OS EFS(RFS) 75.00 %
De Bruyne S et al. [22] 2012 19 Retrospective Pretreatment and
posttreatment
Chemotherapy
and bevacizumab
EFS(PFS) 75.00 %
Lastoria S et al. 2013 33 Retrospective Pretreatment and
posttreatment
Chemotherapy and
Bevacizumab
EFS(PFS) OS 66.67 %
Mertens J et al. [23] 2013 18 Prospective Pretreatment and
posttreatment
Chemotherapy
and Bevacizumab
OS 75.00 %
Zerizer I et al. 2013 25 Retrospective Pretreatment and
posttreatment
90Y radioembolization EFS(PFS) 70.83 %
Fendler W P et al. 2013 80 Retrospective Pretreatment and
posttreatment
90Y radioembolization OS 62.50 %
Jones C et al. 2014 79 retrospective Pretreatment Resection OS 54.17 %
Lee HS et al. [24] 2014 120 retrospectively Pretreatment Resection OS EFS(RFS) 83.33 %
Lau LF et al. 2014 37 retrospective Pretreatment and
posttreatment
Chemotherapy OS EFS(RFS) 58.33 %
Riedl CC et al. [25] 2007 90 retrospective Pretreatment Resection OS 54.17 %
Correa-Gallego C et al. 2015 38 Prospective Pretreatment and
posttreatment
Chemotherapy
and bevacizumab
OS EFS(PFS) 83.33 %
Sabet A et al. 2015 51 retrospective Pretreatment and
posttreatment
90Y radioembolization OS 70.83 %
a"end points": time elapsed between treatment initiation and disease progression or death
Table 3 Main SUV (pretreatment or posttreatment) characteristics extracted from the 9 articles used for meta-analysis
study Type of SUV Correction of SUV Threshold definition SUV threshold
de Geus-Oei L F et al. preSUVmean Body weight Median >4.26
Muralidharan V et al. preSUVmean Body weight Best cut-off >10
De Bruyne S et al. postSUVmax Body weight Median >2.85
Mertens J et al. postSUVmax Body weight Median 2.85
Claire Jones.et al. PreSUVmean Body weight Arbitrary >7.0
Lee HS et al. PreanSUVpeak Body weight Median >5.0
Lau LF et al. postSUVmax Body weight Previous report >10
Riedl CC et al. preSUVmax Body weight Best cut-off >10
Correa-Gallego C et al. preSUVmax Body weight Median >10
anSUVpeak: normalized SUVpeak
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prognostic factor in liver metastases [26, 27], but some
studies have not found a significant association between
SUV and prognosis [28–30]. Apparently, there have been
controversial results. Therefore, we have elaborated this
meta-analysis to evaluate the prognostic value of 18FDG
PET-CT for liver metastases.
This meta-analysis has provided two meaningful find-
ings regarding the use of 18FDG-PET for predicting sur-
vival of patients with liver metastases. First, some
studies do have addressed the predictive value of pa-
tients with metabolically nonresponding liver metastases
after treatment for OS and EFS. Through our quantita-
tive analysis, the risk of death in nonresponding group
was 2.5 times as high as the responding group in OS
and 2.632 times in EFS. We assumed that these tumors
are more aggressive or invasive with hyperactive metab-
olism as displayed in 18FDG PET/CT images. Although
a range of factors has been associated with 18FDG up-
take, there appears to be a rather strong relationship be-
tween 18FDG uptake and cancer cell mass in a number
of studies [31, 32]. The metabolic response, which might
be the strongest marker of prognosis, was measured in
tumors that were ultimately resected. It appeared that
the value of metabolic response was not just for the
evaluation of the visible hepatic lesions but also for serv-
ing as an indicator for the sensitivity to chemotherapy
among potentially undetectable micro-metastases.
Current imaging technologies have limitations in reso-
lution, with PET systems being able to detect tumors as
small as 0.3–0.7 cm. This corresponds to a minimum
detectable tumor size with about 108–109 cells [33].
Consequently, it is reasonable that declined tumor SUV
would be seen with a loss of viable cancer cells, and in-
creased tumor glucose use and volume of tumor cells
would be expected in progressive tumors. The evaluation
of metabolic response before planned resection of liver
metastases includes the strengths of being noninvasive,
repeatable, quantifiable and discriminative towards clin-
ical outcomes. At present, 18FDG PET/CT appears to be
the best prognostic tool available for the oncologists in
the field of hepatobiliary surgery [34].
Secondly, our meta-analyses on the prognostic value
of pre-treatment SUV measured on metastatic sites also
showed that high SUV was an independent prognostic
factor for poorer OS. By quantitative analyses, the risk of
death in high SUV group was 1.12 times the low SUV
Table 4 Main ΔSUV characteristics extracted from the 8 articles used for meta-analysis
Study Type of SUV Correction of SUV Threshold definition SUV threshold
Small RM et al. aΔSUV Body weight Visual observation unclear
Hendlisz A et al. ΔSUVmax Body weight bEORTC metabolic decrease > 25 %
De Bruyne S et al. ΔSUVmax Body weight EORTC metabolic decrease > 25 %
Lastoria S et al. ΔSUVmax Body weight Median metabolic decrease > 50 %
Zerizer I et al. ΔSUVmax Body weight Best cut-off metabolic decrease > 2.0
Fendler W P et al. ΔSUVmax Body weight cPERCIST metabolic decrease > 30 %
Correa-Gallego C et al. ΔSUVmax Body weight dWHO metabolic decrease > 25 %
Sabet A et al. ΔSUV Body weight Best cut-off metabolic decrease > 50 %
aΔSUV : difference between baseline and follow-up SUVmax values
bEORTC: The criteria of the European Organisation for Research and Treatment of Cancer
cPERCIST: PET Response Criteria in Solid Tumors
d WHO: WHO Criteria
Fig. 2 Forest plot of 7 included studies in ΔSUV for EFS. Pooled effect (HR) and heterogeneity test of a metabolic responding on EFS in patients
with liver metastases (EFS: event-free survival; HR: hazard ratio)
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group in OS (95%CI 0.01–0.25, P = 0.04), no matter
whether patients subsequently underwent curative sur-
gery or chemotherapy. This is most likely due to the fact
that high SUV tumors are more aggressive and meta-
static, thus leading to relatively worse prognosis. One-
unit increase in SUV could correspond to a significant
increase of 17 % in the risk of death [35]. Thus, our data
suggest that intense glucose metabolism in liver metasta-
ses is a negative marker of prognosis. However, there
existed large discrepancies among the cutoff values to
distinguish high SUV from low SUV PET results (thresh-
olds varying from 2.85 to 20). Higashi et al. [36] and
Vansteenkiste et al. [37] indicated that dichotomization
with a wide-ranging of SUVs gave significantly discrim-
inative log-rank probability values. This suggests that the
relationship between SUV and prognosis could be a
gradual one rather than based on a threshold. The wide
range of SUV thresholds seen in these articles can be
due to several factors such as institution-based technical
variations, the heterogeneity of the patient cohorts ana-
lyzed and the variance in the PET scanners and acquisi-
tion protocols used.
As subjective criteria were used in some studies
(Table 3), despite such variability, we were able to show
that the SUV was indeed correlated with patient survival.
In our study, we summarized an HR from individual arti-
cles based on the SUV threshold used in each particular
study, which helped to cancel the threshold factor to a
certain extent. By doing so, we could demonstrate that the
SUV was surely worth considering as a prognostic factor
in patients with liver metastases. In addition, only three
studies dealing with the predictive value of post-treatment
SUV for OS were included. One of these two studies with
a total of 18 patients indicated significant OS benefit of
low SUV after treatment, but another study with 37 pa-
tients showed an opposite conclusion. Summary of results
showed that between high SUV and low SUV groups, no
statistically significant effect was found (95 %, CI 0.63–
4.52; P = 0.08). This lack of significance could be explained
by insufficient study inclusion for the present analyses,
which did not allow a definite conclusion in this aspect. In
future studies, we should collect more similar type of
studies for more comprehensive research.
There exist a number of limitations in our study. First,
our meta-analysis was restricted to articles published
only in English. Secondly, the methodology used did not
prevent all of the potential biases (e.g. Additional file 1:
Figure S1; Additional file 2: Figure S2; Additional file 3:
Figure S3; Additional file 4: Figure S4), which was par-
tially due to the fact that studies with nonstatistically
Fig. 3 Forest plot of 7 included studies in ΔSUV for OS. Pooled effect (HR) and heterogeneity test of a metabolic responding on OS in patients
with liver metastases (OS: overall survival)
Fig. 4 Forest plot of 6 included studies in pretreament SUV for OS. Pooled HR compared low SUV group with high SUV group in patients with
liver metastases
Xia et al. Cancer Imaging  (2015) 15:19 Page 7 of 9
significant results were less often published. Third, the
clinical heterogeneity may also account for the test re-
sults, since among included studies patients received dif-
ferent therapies (e.g. various chemotherapy schemes
with or without bevacizumab and the types of surgery or
surgical techniques) that may all influence the outcomes.
Last but not least, some of the included studies did not
provide sufficient data of time-to-event outcomes for
meta-analysis directly. We had to use Engauge Digitizer
to extract data from survival curves, which may result in
certain inaccuracy. Nevertheless, the validity of the
major findings in this study has been supported by more
recent clinical studies [38, 39].
Conclusion
In conclusion, the present meta-analysis confirms that
the patients before treatment with high SUV 18FDG
PET/CT images and patients with metabolically nonre-
sponding 18FDG PET/CT images may be considered at
high risk of death or treatment failure. Therefore, the
SUV of 18 FDG PET/CT is a useful tool to help predict
survival outcomes in colorectal cancer patients with liver
metastases.
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